

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Tosato *et al.*

**Patent No.** 6,867,180

**Issued:** March 15, 2005

**Application No.** 09/807,148

**Filed:** April 5, 2001

**Confirmation No.** 2215

**For:** USE OF CALRETICULIN AND CALRETICULIN  
FRAGMENTS TO INHIBIT ENDOTHELIAL CELL  
GROWTH AND ANGIOGENESIS, AND SUPPRESS  
TUMOR GROWTH

**Examiner:** Misook Yu, Ph.D.

**Art Unit:** 1642

**Attorney Reference No.** 4239-58378-01

**FILED VIA EFS**

FILED VIA THE ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

**REQUEST FOR SECOND CERTIFICATE OF CORRECTION**

The following errors were noted in comparing the printed patent with the papers  
in the attorneys' files:

**In the Specification:**

Column 18, line 26, Table 2, is missing the "Inhibition percentage value" for the first  
line. Thus, "1.<sup>a</sup> None 142 " should read --1.<sup>a</sup> None 142 44--.

Column 22, line 11, Table 4, "1.<sup>a</sup> None 142 44" (as this Table was corrected to  
read in the June 29, 2009 Request for Certificate of Correction) should read  
--bBGF+GST-calreticulin 9,870 44--.

Since at least one of the errors is not attributable to the Patent Office, the fee of  
\$100.00 pursuant to 37 C.F.R. 1.20(a) is submitted herewith. The preceding corrections  
remedy mistakes of a typographical nature and/or minor character. A proposed  
Certificate of Correction is also provided, to make formal notice of the errors in the

referenced patent. Applicants request that the Patent Office provide a formal Certificate of Correction to correct the errors noted herein.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630

cc: Docketing/Client